Last reviewed · How we verify
SIM1811-03
At a glance
| Generic name | SIM1811-03 |
|---|---|
| Also known as | SIM0235, TNFR2 monoclonal antibody |
| Sponsor | Jiangsu Simcere Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase I Trial of SIM1811-03 in Subjects With Advanced Tumors (PHASE1)
- A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SIM1811-03 CI brief — competitive landscape report
- SIM1811-03 updates RSS · CI watch RSS
- Jiangsu Simcere Pharmaceutical Co., Ltd. portfolio CI